Stockscreener 앱 받기
9.05
0.98%
-0.09
시간 외 거래:
8.94
-0.11
-1.22%
전일 마감가:
$9.14
열려 있는:
$9.23
하루 거래량:
874.19K
Relative Volume:
0.60
시가총액:
$803.30M
수익:
$67.48M
순이익/손실:
$-278.67M
주가수익비율:
-2.8482
EPS:
-3.1774
순현금흐름:
$-70.70M
1주 성능:
+2.96%
1개월 성능:
+4.62%
6개월 성능:
-12.05%
1년 성능:
+50.08%
1일 변동 폭
$8.895
$9.279
1주일 범위
$8.58
$9.279
52주 변동 폭
$5.45
$12.49
Kura Oncology Inc Stock (KURA) Company Profile
명칭
Kura Oncology Inc
전화
(858) 500-8800
주소
4930 DIRECTORS PLACE, SUITE 500, SAN DIEGO, CA
Compare KURA vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KURA
Kura Oncology Inc
|
9.05 | 811.29M | 67.48M | -278.67M | -70.70M | -3.1774 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Kura Oncology Inc Stock (KURA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-04 | 개시 | Guggenheim | Neutral |
| 2025-02-06 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-10-14 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-12-22 | 개시 | Mizuho | Buy |
| 2023-08-11 | 개시 | BofA Securities | Buy |
| 2023-07-27 | 개시 | Scotiabank | Sector Perform |
| 2023-05-17 | 개시 | BTIG Research | Buy |
| 2023-01-31 | 개시 | Stifel | Buy |
| 2022-07-12 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-02-15 | 개시 | Jefferies | Buy |
| 2021-05-05 | 재개 | Credit Suisse | Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2020-12-07 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-03 | 개시 | Stifel | Buy |
| 2020-11-05 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | 개시 | Credit Suisse | Outperform |
| 2020-05-05 | 개시 | Barclays | Overweight |
| 2019-07-18 | 개시 | Deutsche Bank | Buy |
| 2018-11-09 | 개시 | Piper Jaffray | Overweight |
| 2018-08-01 | 개시 | H.C. Wainwright | Buy |
| 2016-10-13 | 재개 | Leerink Partners | Outperform |
| 2016-01-22 | 개시 | JMP Securities | Mkt Outperform |
| 2015-12-30 | 개시 | Oppenheimer | Outperform |
| 2015-12-16 | 개시 | Citigroup | Buy |
모두보기
Kura Oncology Inc 주식(KURA)의 최신 뉴스
Kura Oncology, Inc. (NASDAQ:KURA) Q4 2025 earnings call transcript - MSN
KURA Initiates Coverage On Lake Street -- Price Target Announced at $23 - GuruFocus
Aug Drivers: What are the future prospects of Kura Oncology IncMarket Growth Report & Daily Profit Maximizing Trade Tips - baoquankhu1.vn
[ARS] Kura Oncology, Inc. SEC Filing - Stock Titan
Kura Oncology (NASDAQ: KURA) plans votes on pay, equity plan and auditor - Stock Titan
Bond Watch: Why is Kura Oncology Inc stock going up2026 Market Mood & Risk Managed Investment Signals - baoquankhu1.vn
KURA News | KURA ONCOLOGY INC (NASDAQ:KURA) - ChartMill
Kura to unveil new kidney cancer combo data in previously treated patients - Stock Titan
Kura Oncology to Present Darlifarnib Plus Cabozantinib Data in Patients with Clear Cell Renal Cell Carcinoma Previously Treated with Cabozantinib at IKCS Europe 2026 - Bitget
Breakout Move: Is Kura Oncology Inc vulnerable to short sellers2026 Market Sentiment & Safe Swing Trade Setup Alerts - baoquankhu1.vn
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sahm
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule - National Today
Kura Oncology Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Kura Oncology Grants Inducement Stock Options to New Employees as Part of 2023 Inducement Option Plan - Quiver Quantitative
Kura Oncology (NASDAQ:KURA) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
Kura Oncology: Commercialization In AML Presents Asymmetric Upside (NASDAQ:KURA) - Seeking Alpha
Vanguard reports 0% ownership in Kura Oncology (NASDAQ: KURA) - Stock Titan
Kura Oncology Inc (HAM:KUR) Stock Price, Trades & News - GuruFocus
Kura Oncology (NASDAQ: KURA) CEO exercises options, increases share stake - Stock Titan
Mizuho Cuts Price Target on Kura Oncology to $25 From $30, Keeps Outperform Rating - marketscreener.com
Kura Oncology, Inc. (NASDAQ:KURA) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Kura Oncology, Inc. (NASDAQ:KURA) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Mizuho Cuts Kura Oncology (NASDAQ:KURA) Price Target to $25.00 - MarketBeat
Mizuho cuts Kura Oncology stock price target on delayed sales By Investing.com - Investing.com Canada
Mizuho Securities Maintains Kura Oncology(KURA.US) With Buy Rating, Cuts Target Price to $25 - Moomoo
Kura Oncology Inc stock surges on positive mid-stage trial results for key cancer drug candidate - AD HOC NEWS
KURA SEC FilingsKura Oncology Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Jobs Data: Is Kura Oncology Inc a strong candidate for buy and holdMarket Sentiment Report & Trade Opportunity Analysis Reports - baoquankhu1.vn
Kura Oncology (KURA) director exercises 10,000 options for shares - Stock Titan
Kura Oncology Inc Stock (ISIN: US50126D1028) Faces Post-Earnings Pressure Amid Komzifti Launch Chall - AD HOC NEWS
Kura Oncology anticipates $7B AML opportunity as KOMZIFTI launches and combination strategies advance - MSN
UBS Maintains Buy on KURA (Kura Oncology) March 2026, PT $15 - Meyka
Prosight Management LP Sells 422,668 Shares of Kura Oncology, Inc. $KURA - MarketBeat
KURA: UBS Analyst Maintains 'Buy' Rating But Lowers Price Target | KURA Stock News - GuruFocus
UBS lowers Kura Oncology stock price target to $15 on launch data - Investing.com Canada
Implied volatility surging for Kura Oncology stock options - MSN
Implied Volatility Soars for Kura Oncology Option Contracts - Bitget
Kura Oncology at Barclays Conference: Strategic Focus on Drug Combinations - Investing.com Canada
Implied Volatility Surging for Kura Oncology Stock Options - TradingView
KURA: Komzifti and ziftomenib advance with strong launch, global trials, and promising pipeline updates - TradingView — Track All Markets
(KURA) Risk Channels and Responsive Allocation - Stock Traders Daily
Kura Oncology Inc earnings missed by $0.66, revenue fell short of estimates - Investing.com Nigeria
Kura Oncology at Leerink Global Healthcare Conference: Strategic Expansion Insights - Investing.com Canada
KURA: Rapid market access and robust pipeline drive growth and leadership ambitions in precision oncology - TradingView
KURA: Multiple clinical readouts and strong commercial momentum position for leadership in targeted oncology - TradingView
FY2027 EPS Forecast for Kura Oncology Lowered by Analyst - MarketBeat
How The Kura Oncology (KURA) Story Is Shifting With Komzifti And New Street Targets - Yahoo Finance
UBS Reaffirms Their Buy Rating on Kura Oncology (KURA) - The Globe and Mail
Kura Oncology rises after new early-stage trial data for leukemia therapy - MSN
Jim Cramer discusses Kura Oncology as a speculative bet - MSN
Kura Oncology 2025 Financials: Q4 Loss Widens, Misses Analyst EstimatesNews and Statistics - IndexBox
Kura Oncology Inc (KURA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.69%
0.25%
자본화:
|
볼륨(24시간):